BLOG

pharma shots

Tim Clackson, President & CEO of Theseus Pharmaceuticals, Shares Insights on its Pan-Variant Inhibitor Therapies to Treat Cancer

Theseus’ pan-variant inhibitor candidates are designed to outsmart cancer treatment resistance by precluding that “arms race.” Pan-variant inhibitors are single therapeutic agents that maintain their anti-cancer activity against a target protein in the face of any and all major classes of cancer-causing and resistance mutations.